Literature DB >> 21628938

Diffuse large B-cell lymphoma complicated with autoimmune thrombocytopenia.

Michihiro Uchiyama1, Kota Sato, Takashi Ikeda.   

Abstract

A patient was diagnosed with autoimmune thrombocytopenia and concurrent diffuse large B-cell lymphoma (DLBCL). Both autoimmune thrombocytopenia and DLBCL were successfully treated using chemotherapy, while steroid therapy, rituximab monotherapy, and high-dose parenteral glucocorticoid therapy combined with high-dose intravenous immunoglobulin failed to improve thrombocytopenia. A greater understanding of the pathogenesis and treatment options can only be definitively clarified by analyses of settings such as the present case, as autoimmune thrombocytopenia is uncommon in patients with malignant lymphoma and the etiology and optimal treatment remain unclear.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21628938     DOI: 10.2169/internalmedicine.50.4848

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

Review 1.  Treatment of Secondary Immune Thrombocytopenia with Non-Hodgkin Lymphoma: A Case Report and Literature Review.

Authors:  Yuya Kurihara; Kazuki Taoka; Eri Takagi; Kazuhiro Toyama; Kumi Nakazaki; Mineo Kurokawa
Journal:  Intern Med       Date:  2021-05-15       Impact factor: 1.271

2.  Synchronous Occurrence of Diffuse Large B-cell Lymphoma of the Duodenum and Gastrointestinal Stromal Tumor of the Ileum in a Patient with Immune Thrombocytopenic Purpura.

Authors:  Tohru Takahashi; Yumiko Maruyama; Mayuko Saitoh; Hideto Itoh; Mitsuru Yoshimoto; Masayuki Tsujisaki; Masato Nakayama
Journal:  Intern Med       Date:  2016-10-15       Impact factor: 1.271

3.  Successful Treatment of Aggressive Mature B-cell Lymphoma Mimicking Immune Thrombocytopenic Purpura.

Authors:  Koya Ono; Yasushi Onishi; Masahiro Kobayashi; Satoshi Ichikawa; Shunsuke Hatta; Shotaro Watanabe; Yoko Okitsu; Noriko Fukuhara; Ryo Ichinohasama; Hideo Harigae
Journal:  Intern Med       Date:  2018-03-30       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.